教育背景
2001-2005 清华大学生命科学与技术系 学士
2005-2011 美国哥伦比亚大学 博士
工作经历
2012-2017 美国洛克菲勒大学 博士后
2017-2022 清华大学医学院 助理教授
2022-2024 清华大学医学院 副教授
2024-至今 清华大学基础医学院 副教授
研究领域
肿瘤表观遗传学。陈默课题组的主要研究方向是揭示表观遗传调控因子和转录因子如何通过调控癌症特异性转录程序来影响肿瘤的发生。实验室采用先进的基因组学技术、生物化学、分子生物学方法，并结合体内小鼠模型，致力于解决癌症生物学中的前沿问题。近期，本实验室的研究重点集中在胰腺癌早期发展过程中的染色质动态变化。通过一系列深入且创新的研究，我们致力于阐明早期胰腺癌中关键祖细胞产生的决定性因素和相关的分子机制。相信这项研究的实施将带来癌症表观遗传学领域的新理论突破，并为胰腺癌的精准治疗提供坚实的理论基础。与此同时，本实验室还对转录调控的基本问题保持浓厚兴趣，具体包括：RNA是如何从基因中转录出来的？不同类型的非编码RNA之间有何区别？以及它们背后的潜在分子机制是什么？
科学贡献
先后揭示胰腺癌发生过程中的决定成体胰腺细胞可塑性的机制；鉴定可以区分胰腺组织再生和癌变的关键表观遗传事件和因子；阐述癌症依赖的增强子RNA的调控机制。通过这些创新性研究成果，为理解癌症的分子机制提供了新的视角，关注癌症特别是胰腺癌发生发展过程中的表观遗传现象，鉴定表观遗传靶点，目标开发新一代肿瘤药物提供理论基础。迄今在包括Nature、Nature Structural & Molecular Biology在内的国际期刊上发表学术论文17篇，总引用超过4000次。
荣誉奖励
2023 北京市杰出青年
2023 中国细胞生物学学会女性科学家职业发展基金A类
2018 国家级青年人才项目
2016 美国NIH K22award （已经拒绝）
2015 Women in Science award
2012 Leukemia & Lymphoma Society award
2011 John S. Newberry Award
2010 国家优秀自费留学生奖学金
代表性论文
1.Chen M* (2024) Puff, the polytene chromosome: visualizing transcription elongation control. Molecular Cell. Aug 8. In press.
2.Liu X, Liu X, Du Y, Zou D, Tian C, Li Y, Lan X, David C, Sun Q, Chen M* (2023) Aberrant accumulation of Kras-dependent enhancer RNAs and PROMPTs during tumor progression renders cancer cells susceptible to PAF1 depletion. Cell Reports 42,112979.
3.Chen M* (2023) CircR-looping the leukemic translocations: The cause of MLL-translocations explained. Molecular Cell 83:2164-2166.
4.Chen Q, Cevher MA, Jiang Q, Wang S, Sun XJ, Roeder RG*, Chen M*(2022)LYL1 facilitates AETFC assembly and gene activation by recruiting CARM1 in t(8;21) AML. Proc Natl Acad Sci U S A 119, e2213718119.
5.Guo Z, Liu X, Chen M*(2022) Defining pervasive transcription units using chromatin RNA-sequencing data. STAR Protoc 3, 101442.
6.Liu X, Guo Z, Han J, Peng B, Zhang B, Li H, Hu X, David C, Chen M*(2022) The PAF1 complex promotes 3’ processing of pervasive transcripts. Cell Reports 38,110519.
7.Meng J, Zhao S, Tao Y, Zhang T, Wang X, Zhang Y, Sun K, Yuan M, Chen J, Wei Y, Lan X, Chen M*, David C, Chang Z, Guo X, Pan D, Chen M, Shao Z*, Kang Y*, Zheng H* (2022) Tumor-derived Jagged1 promotes cancer progression through immune evasion. Cell Reports38, 110492.
8.Li Y#, He Y#, Peng J#, Li Z, Zhang B, Ma J, Zhuo M, Zou D, Liu X, Liu X, Wang W, Huang D, Xu M, Wang J, Deng H, Xue J, Xie W, Lan X, Chen M, Zhao Y*, Wu W* and David C* (2021) Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Nature Cancer 2:49-65. （#equal contribution）
9.David C, Huang Y, Chen M, Su J, Zou Y, Bardeesy N, Iacobuzio-Donahue C, Massagué J (2016)TGF-β Tumor Suppression Through A Lethal EMT. Cell 164:1015-30.
10.Zhu N, Chen M, Eng R, Sinha AU, Rahnamay N, Koche R, Al-Shahrour F, Minehart J, Chen C, Deshpande A Xu H, S. Chu H, Ebert B, Roeder R, Armstrong S (2016) Jmjd1c is required for MLL-AF9 and HOXA9 Mediated AML Stem Cell Self-Renewal. J Clin Invest126:997-1011.
11.Chen M, Zhu N, Liu X, Laurent B, Tang Z, Eng R, Shi Y, Armstrong S, Roeder R (2015) JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes Dev 29:2123-2139.
12.Chen M, David C, Manley J (2012) Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins. Nat Struct Mol Biol 19:346-U110.
13.Chen M, David C, Manley J (2010) Tumor metabolism: hnRNP proteins get in on the act. Cell Cycle 9: 1863-1864.
14.Chen M, Zhang J, Manley J (2010) Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res.70:8977-8980.
15.David C#, Chen M#, Assanah M, Canoll P, Manley J(2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364-U114.
16.Chen M, Manley J (2009) Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 10:741-754.
17.Feng Y, Chen M, Manley J(2008) Phosphorylation switches the general splicing repressor SRp38 to a sequence-specific activator. Nat Struct Mol Biol 15:1040-1048.
